Skip to main content

Sources last read

Mental health · FDA safety review

GLP-1s and mental health

FDA finished its review in 2026. It found no added risk of suicidal thoughts or acts from GLP-1 drugs. FDA then asked drug makers to remove the warning from Saxenda, Wegovy and Zepbound. This does not show that the drugs help mental health or explain one person’s symptoms.

Source: FDA Drug Safety Communications, read 2026-08-16

What matters first

FDA review
No added risk of suicidal thoughts or acts
Warning removal
Requested for Saxenda, Wegovy and Zepbound
Mental-health benefit
Not established by this review
Urgent support
Call or text 988 in the U.S.

Regulatory timeline

The answer changed because the review finished

January 2024

Preliminary signal review

FDA found no proof that GLP-1 drugs caused suicidal thoughts or acts.

Boundary: Trials had few such events. FDA could not rule out a small risk, so it kept studying the issue.

January 13, 2026

Final comprehensive review

FDA found no added risk of suicidal thoughts or acts. It said the full set of evidence did not support a causal link.

Boundary: This was a safety review for a drug class. It did not test these drugs as care for anxiety, depression or other mental-health needs.

The final review

What FDA analyzed

91

Placebo-controlled trials

Of 107,910 people, 60,338 used a GLP-1 drug. The other 47,572 used a placebo.

2,243,138

People in the Sentinel cohort

FDA compared 1,161,983 new GLP-1 users with 1,081,155 new users of SGLT2 inhibitors.

The trial review found no added risk of suicidal thoughts or acts. The Sentinel study also found no added risk of intentional self-harm. FDA saw no added risk in the groups it checked for anxiety and depression.

Label action

Three weight-management labels were affected

SaxendaWegovyZepbound

FDA asked drug makers to remove the warning about suicidal thoughts or acts from all three labels.

What that does not mean: this was a safety review of a drug class. It cannot tell why one person has a new mood symptom. It cannot prove that no one will have one. It also does not show that a GLP-1 drug helps mental health. FDA still says to tell a health professional about new or worse depression, suicidal thoughts, or odd shifts in mood or behavior.

Continue with the relevant safety record

Side effects by symptomLook up the symptom first. Do not assume one drug caused it.Semaglutide side effectsRead the source-backed record for semaglutide.Tirzepatide side effectsRead the source-backed record for the drug in Mounjaro and Zepbound.How medical review worksSee what the reviewer checks and signs.

Review boundary

Medically reviewed by Jennifer Montecillo, MD · non-practicing medical reviewer

Reviewed 2026-08-16

FDA’s review and the resulting label changes are summarized below. They cannot explain one person’s symptoms. It does not replace urgent help. It also does not show a mental-health benefit.

3primary sources, each with the day we read it — open the documents used on this page